Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

Cited In for PubMed (Select 10331505)

1.

Management of thrombocythemia.

Gowin K, Mesa R.

F1000Res. 2014 Sep 29;3:227. doi: 10.12688/f1000research.5361.1. eCollection 2014.

2.

Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN).

Price GL, Davis KL, Karve S, Pohl G, Walgren RA.

PLoS One. 2014 Mar 11;9(3):e90299. doi: 10.1371/journal.pone.0090299. eCollection 2014.

3.

Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review.

Mitra D, Kaye JA, Piecoro LT, Brown J, Reith K, Mughal TI, Sarlis NJ.

Cancer Med. 2013 Dec;2(6):889-98. doi: 10.1002/cam4.136. Epub 2013 Oct 5.

4.

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.

Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP.

Leuk Res. 2014 Mar;38(3):316-22. doi: 10.1016/j.leukres.2013.12.006. Epub 2013 Dec 11.

5.

Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.

Choong ML, Pecquet C, Pendharkar V, Diaconu CC, Yong JW, Tai SJ, Wang SF, Defour JP, Sangthongpitag K, Villeval JL, Vainchenker W, Constantinescu SN, Lee MA.

J Cell Mol Med. 2013 Nov;17(11):1397-409. doi: 10.1111/jcmm.12156. Epub 2013 Nov 19.

6.

Expanding the SHOC2 mutation associated phenotype of Noonan syndrome with loose anagen hair: structural brain anomalies and myelofibrosis.

Gripp KW, Zand DJ, Demmer L, Anderson CE, Dobyns WB, Zackai EH, Denenberg E, Jenny K, Stabley DL, Sol-Church K.

Am J Med Genet A. 2013 Oct;161A(10):2420-30. doi: 10.1002/ajmg.a.36098. Epub 2013 Aug 5.

7.

When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms.

Oh ST.

Ther Adv Hematol. 2011 Feb;2(1):11-9. doi: 10.1177/2040620710393391.

8.

Emerging therapeutic options for myelofibrosis: a Canadian perspective.

Gupta V, Foltz L, Sirhan S, Busque L, Turner AR.

Am J Blood Res. 2012;2(3):170-86. Epub 2012 Sep 23.

9.

Acute Myeloid Leukemia Evolving from JAK 2-Positive Primary Myelofibrosis and Concomitant CD5-Negative Mantle Cell Lymphoma: A Case Report and Review of the Literature.

Treaba DO, Khedr S, Mangray S, Jackson C, Castillo JJ, Winer ES.

Case Rep Hematol. 2012;2012:875039. doi: 10.1155/2012/875039. Epub 2012 Aug 2.

10.

Fifty years of melphalan use in hematopoietic stem cell transplantation.

Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO.

Biol Blood Marrow Transplant. 2013 Mar;19(3):344-56. doi: 10.1016/j.bbmt.2012.08.011. Epub 2012 Aug 24. Review.

11.

Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.

Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, Dickman PW, Björkholm M.

J Clin Oncol. 2012 Aug 20;30(24):2995-3001. doi: 10.1200/JCO.2012.42.1925. Epub 2012 Jul 16.

12.

The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.

Kirabo A, Park SO, Wamsley HL, Gali M, Baskin R, Reinhard MK, Zhao ZJ, Bisht KS, Keserű GM, Cogle CR, Sayeski PP.

Am J Pathol. 2012 Sep;181(3):858-65. doi: 10.1016/j.ajpath.2012.05.033. Epub 2012 Jul 13.

13.

Essential thrombocythemia in a young man treated for myocardial infarction.

Pande S, Joshi R, Pande R.

BMJ Case Rep. 2010 Aug 3;2010. pii: bcr0920092234. doi: 10.1136/bcr.09.2009.2234.

14.

Ruxolitinib for the treatment of myelofibrosis: its clinical potential.

Ostojic A, Vrhovac R, Verstovsek S.

Ther Clin Risk Manag. 2012;8:95-103. doi: 10.2147/TCRM.S23277. Epub 2012 Mar 1.

15.

One thousand patients with primary myelofibrosis: the mayo clinic experience.

Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, Begna KH, Al-Kali A, Ketterling RP, Hanson CA, Pardanani A.

Mayo Clin Proc. 2012 Jan;87(1):25-33. doi: 10.1016/j.mayocp.2011.11.001.

16.

The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.

Kirabo A, Park SO, Majumder A, Gali M, Reinhard MK, Wamsley HL, Zhao ZJ, Cogle CR, Bisht KS, Keserü GM, Sayeski PP.

Neoplasia. 2011 Nov;13(11):1058-68.

17.

JAK2 inhibitors: what's the true therapeutic potential?

Santos FP, Verstovsek S.

Blood Rev. 2011 Mar;25(2):53-63. doi: 10.1016/j.blre.2010.10.004. Epub 2010 Nov 20. Review.

18.

Factors affecting prognosis in myelofibrosis.

Onida F.

F1000 Med Rep. 2009 Jul 8;1. pii: 55. doi: 10.3410/M1-55.

19.
20.

Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.

Merker JD, Jones CD, Oh ST, Schrijver I, Gotlib J, Zehnder JL.

J Mol Diagn. 2010 Jan;12(1):58-64. doi: 10.2353/jmoldx.2010.090068. Epub 2009 Dec 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk